Advisors Asset Management, Inc. Seagen Inc. Transaction History

Advisors Asset Management, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$187.64 - $206.25 $985,297 - $1.08 Million	-5,251 Reduced 30.77%	11,814 $2.27 Million
Q1 2023 May 12, 2023	SELL	$127.59 - $203.08 $73,109 - $116,364	-573 Reduced 3.25%	17,065 $3.46 Million
Q3 2022 Nov 08, 2022	SELL	$135.27 - $180.11 $15,285 - $20,352	-113 Reduced 0.47%	23,724 $3.25 Million
Q2 2022 Aug 08, 2022	SELL	$108.81 - $179.33 $130,572 - $215,196	-1,200 Reduced 4.79%	23,837 $4.22 Million
Q1 2022 May 17, 2022	BUY	$119.61 - $157.85 $29,304 - $38,673	245 Added 0.99%	25,037 $3.61 Million

Q4 2021 Feb 15, 2022	BUY	$142.57 - $190.86 $408,035 - $546,241	2,862 Added 13.05%	24,792 $3.83 Million
Q3 2021 Nov 12, 2021	BUY	$142.45 - $169.82 $214,529 - $255,748	1,506 Added 7.37%	21,930 $3.72 Million
Q2 2021 Jul 30, 2021	BUY	$135.08 - $161.1 $327,433 - $390,506	2,424 Added 13.47%	20,424 $3.23 Million
Q1 2021 May 07, 2021	BUY	$137.51 - $190.8 $2.48 Million - $3.43 Million	18,000 New	18,000 $2.5 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisors Asset Management, Inc. with notifications on news.